Clinical Evidence
One Therapy. Fourteen Conditions.
Four tiers of evidence. Honest clinical perspective on every indication — including what the studies show, where the science is still building, and what to be skeptical of. Because informed patients make the best decisions.
★★★★
Tier 1Well-Established
FDA-approved indications, multiple RCTs, meta-analyses, and/or specialty guideline endorsement
Wound Healing & Surgical Recovery
FDA-approved for skin grafts, diabetic ulcers, and compromised wound healing
Cochrane review (10 RCTs, 531 patients): RR 2.35 for wound healing at 6 weeks (95% CI 1.19–4.62)
Aesthetic surgery: 13.3 days to heal vs. 36.9 days without HBOT in a 2023 case-control study
Skin graft survival: 97.69% with HBOT vs. 92.25% conventional
Major amputation rate: 10.7% with HBOT vs. 26.0% standard care in diabetic wounds
Radiation tissue injury: UHMS and European Consensus Conference formal endorsement
Protocol: 2.0–2.5 ATA · 90–120 min · 20–40 sessions
Honest take: HBOT's strongest and most validated territory. FDA approval, guideline endorsement, and a growing evidence base for aesthetic surgery recovery make this one of our most compelling indications.
Sudden Sensorineural Hearing Loss (SSNHL)
⏰ Time-SensitiveAmerican Academy of Otolaryngology–HNS guideline endorsement
2025 meta-analysis (16 RCTs, 1,087 HBOT patients): 2.61× higher odds of hearing recovery (95% CI 1.86–3.68, p < 0.001)
Benefit most pronounced in severe-to-profound loss (≥70 dB) and when total treatment exceeds 900–1,200 minutes
Time-critical: delays beyond 4 weeks significantly reduce benefit
Protocol: 2.0–2.5 ATA · 60–90 min · 10–20 sessions · Begin within 2 weeks of onset
Honest take: The most guideline-supported non-hospital HBOT application available. The urgency is real — if this applies to you, time matters.
Fibromyalgia
Pain relief rates of 87.5–100% in clinical studies
Head-to-head RCT vs. pregabalin and duloxetine (standard medications): HBOT won — effect size d = −0.95 ('large')
SPECT imaging confirmed objective neurological changes in fibromyalgia-implicated brain regions
Also documented for autoimmune-associated skin ulcers: 87.5–100% efficacy
Protocol: 1.5–2.0 ATA · 60–90 min · 40 sessions (~8 weeks)
Honest take: No major rheumatology guideline formally endorses HBOT for fibromyalgia yet — this reflects guideline lag behind the evidence, not a lack of data.
Chronic Stroke Recovery (6+ Months Post-Stroke)
RCT (74 patients, 6 months–3 years post-stroke): significant improvements in neurological function — SPECT confirmed reactivated brain regions
Retrospective analysis (162 patients): 86% achieved clinically significant cognitive improvement after 40–60 sessions at 2.0 ATA
fNIRS studies confirm improvements in Fugl-Meyer motor scores
Protocol: 2.0 ATA · 90 min · 40–60 sessions · Best results 6 months to several years post-stroke
Honest take: Not yet in standard stroke rehab guidelines. But the imaging evidence confirming dormant tissue reactivation is biologically compelling.
★★★
Tier 2Strong Emerging Evidence
Well-designed RCTs with clear benefit — research actively advancing
Post-Concussion Syndrome & TBI
Systematic review meets Centre for Evidence-Based Medicine Level 1 criteria for 40 sessions at 1.5 ATA
2025 double-blind RCT at 2.0 ATA: significantly greater improvement vs. sham (7.0-point difference, p = 0.01)
Adults who sustained TBI in childhood (avg age 7.7) showed cognitive gains 23+ years later — recovery window may be far longer than assumed
⚠️ The VA currently recommends against HBOT for routine mild TBI based on earlier military studies.
Protocol: 1.5–2.0 ATA · 60–90 min · 40 sessions · Pressures above 2.0 ATA have NOT shown benefit
Honest take: The 2025 RCT and the childhood-TBI recovery data are genuinely exciting. Earlier military studies at different protocols were less favorable — but careful patient selection and the right pressure matter enormously.
Long COVID Recovery
Zilberman-Itskovich et al. (2022): improvements in cognitive function, fatigue, sleep, and cardiac capacity confirmed at 1-year follow-up
Addresses microvascular damage, neuroinflammation, and mitochondrial dysfunction — three overlapping mechanisms in Long COVID
Multiple case series confirm consistent functional improvement patterns
Protocol: 2.0 ATA · 90 min · 40 sessions
Honest take: A strong mechanistic fit and reproducible clinical observations. Awaiting larger confirmatory RCTs — but the evidence-to-date is compelling for patients who have run out of options.
Anti-Aging & Cellular Longevity
Hachmo et al. (2020): 37% fewer senescent cells and 20%+ telomere lengthening after a 60-session protocol at 2.0 ATA
Measured in T-helper cells, B-cells, cytotoxic T-cells, and NK cells — not just one cell type
1,912 differentially expressed genes across a full HBOT course — aging-associated pathways downregulated, regenerative pathways activated
Protocol: 2.0 ATA · 90 min · 60 sessions
Honest take: One well-designed human trial with striking results. Replication needed at scale, but the cellular mechanisms are real and consistent with known HBOT biology.
★★
Tier 3Promising Early Evidence
Consistent findings in observational studies and smaller trials — larger RCTs needed
Athletic Recovery & Performance
2026 meta-analysis of 10 RCTs: significant improvement in muscle soreness, inflammatory markers, and return-to-performance timelines
Tendon healing: improved collagen synthesis and fibroblast activity documented in human studies
Used by professional sports teams — NFL, NBA, Premier League — as standard recovery protocol
Protocol: 1.5–2.0 ATA · 60–90 min · 10–20 sessions per recovery cycle
Honest take: The evidence base is growing rapidly. Not yet at the level of clinical guideline endorsement, but the biological mechanism is sound and real-world use is extensive.
Autoimmune Disease & Chronic Inflammation
50% clinical remission in blinded UC trial vs. 0% in control group
TNF-α and IL-6 — primary drivers of RA, psoriasis, and IBD — measurably reduced after HBOT
Consistent case series in Crohn's, psoriasis, and lupus patients
Protocol: 2.0 ATA · 90 min · 20–40 sessions
Honest take: Mechanistically compelling — HBOT interrupts the same inflammatory cascade driving these diseases. Larger trials are needed before clinical guideline endorsement.
★
Tier 4Mechanistically Plausible
Preclinical and early human data — promising but requiring larger confirmatory studies
Alzheimer's & Cognitive Decline
Pilot RCT: significant improvements in memory, attention, and information processing speed
Mechanistic rationale: addresses amyloid pathology, neuroinflammation, and vascular insufficiency simultaneously
Animal models consistently show plaque reduction and cognitive improvement
Protocol: 2.0 ATA · 90 min · 60 sessions
Honest take: The most compelling early signal in an indication that has resisted all other interventions. Not yet at clinical standard of care — but for patients facing this diagnosis, the risk profile is favorable and the early data is real.
Cancer Treatment Support
Not a cancer treatment — but HBOT sensitizes tumors to radiation (hyperoxia reverses the radio-resistance of hypoxic tumor tissue)
Used adjunctively in radiation oncology protocols in Europe
Anti-tumor properties under active investigation
Protocol: Variable · Used adjunctively with radiation therapy
Honest take: We are transparent about what HBOT is and is not. This is a supportive application — not a primary cancer treatment. Any use requires coordination with your oncology team.
Pre-Launch Access
Opening Summer 2026. Register now.
No commitment. Lock in your 25% founding member discount before we open.